Healthcare Global Enterprises (HCG) teams up with Accuray to install Tomotherapy H Series with HDA configuration machine for precise treatment of cancer. The new technology now offers faster access treatment and minimises radiation dosage by saving the healthy tissues.
US-based Accuray developed the CyberKnife which is a radio surgery system that has shown to have better outcomes. HCG installed CyberKnife in 2009 that provided the much-needed relief for the treatment of tumour and lesions. To sustain long term partnerships, HCG and Accuray are committed to develop in a phased manner covering site visits, joint scientific talks and training and education to improve skill sets.
Tomotherapy H Series with HDA configuration developed by Accuray, helps in faster planning, faster delivery and increased quality of the treatment. Intensity modulated Radiotherapy (IMRT) is the core of radiotherapy. The machine comes with a fully-integrated 3D image-guided, full spectrum radiation therapy system and builds upon the proven TomoTherapy Hi-Art and TomoHD technologies.
The key features are capable of improving the dose and allows to treat more patients. It also minimises the radiation dose to healthy tissue and critical structures adjacent to the target to reduce treatment time. The result is a balanced treatment delivery that is as unique as each patient. Apart from TomoEDGE, the TomoHDA System is also equipped with the high-performance VoLO Technology that allows ultra-fast creation of highly conformal treatment plans with the flexibility to design a personalized treatment plan specific to the individual needs of each patient, according to HCG.
“With one of the most versatile radiation therapy treatment options available for cancer now, we have become the most comprehensive radiation therapy facility in India along with Cyberknife and Tomotherapy H Series with HDA configuration. With such advanced technology and having performed several complicated surgeries over the years, Tomotherapy’s can treat a full range of disease sites, including even the most complex tumors, makes it an invaluable resource for cancer patients,” said Dr. B.S Ajaikuma, chairman, HCG Enterprises.
“With this first installation of Tomotherapy H Series with HDA configuration in India at HCG, we believe that the clinicians believe in long-term benefits that our technologies can provide to the patients. The dose is not lethal but helps patients survive longer. The advanced equipment is designed to offer personalized radiation treatment using clinical evidence as a technological innovation,” said Dr. Lionel Hadjadjeba, corporate senior vice president – Accuray, a press conclave.
According to Dr. Sindhu Ramamurthy and Dr. Kumara Swamy, radiation oncologists, HCG said, that the Tomotherapy H Series with HDA configuration will allow us to create specialized treatments ranging from high-precision stereotactic body radio therapy for early-stage and localized disease to image-guided, IMRT for more advanced disease throughout the body.